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Table 1
Overall change from admission and transplant to pre-engraftment





Phosphorous 244 Admission (A) -0.6836 0.9956 <.001
Transplant (B) -0.4012 1.0076 <.001
Calcium 242 Admission (A) -0.5851 0.7192 <.001
Transplant (B) -0.0971 0.6008 .0126
Potassium 244 Admission (A) -0.2947 0.5642 <.001
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Signiﬁcance and Background: BMT patients are frequently
discharged to outpatient care with a central line catheter in
place. These patients are at increased risk for developing
a central line- associated bloodstream infection (CLABSI). A
review of literature and comparison CLABSI rates showed
a paucity of studies in the outpatient population. An outpa-
tient who develops a CLABSI usually requires admission to
the hospital, where treatment costs may range from
$35,000-53,000. CLABSI surveillance began in January 2009
for our outpatient BMT population utilizing the same NHSN
deﬁnition used for inpatients. An analysis of data collected
over 18 months prompted nursing staff to implement a plan
to target reduction of CLABSIs.
Interventions: BMT Treatment Center nurses were educated
on CLABSI, current rates, and implications for patients as well
as the department. The nurses researched ways to reduce
CLABSIs and developed a post-insertion bundle for central
line care utilizing CDC CLABSI prevention strategies and other
evidence-based practices. Patient education materials were
developed and a post-line insertion patient education plan
was initiated. Nursing compliance with the bundle is
continuallymonitoredby retrospective reviewsof central line
charting,monthly central line audits, and reviewof electronic
patient education tools. CLABSI surveillance is ongoing with
an in-depth review of all CLABSIs for defects in nursing care.
Results: The 18 month pre-bundle CLABSI rate was 1.66 per
1000 patient visits. The 18 month post-bundle rate fell to
0.88 per 1000 patient visits. The actual number of CLABSIs
fell by 30. This resulted in 30 fewer hospital admissions and
a minimal savings of over $1,000,000 dollars to the facility.
Speciﬁcally, the number of coagulase-negative staph infec-
tions, frequently associated with indwelling devices, drop-
ped from 32 pre bundle to 7 post bundle implementation.
Nursing compliance with CLABSI prevention strategies
continues to be well over 90%.Transplant (B) -0.2279 0.5967 <.001TRANSPLANT NURSING-RESEARCH ORAL119
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Background: The rapid hematopoietic cell expansion that
leads to engraftment after SCT requires variety of metabolicand nutritional factors. Hypophosphatemia, has been re-
ported to precede engraftment (Raanani, et al.). Nurses have
noted and we therefore hypothesized that phosphorous,
calcium, and potassium values would drop 2-4 days pre-
engraftment, when compared to either admission for
conditioning (time point A) or day of transplant (time point
B). Being able to predict neutrophil recovery helps nurses be
alert for clinical signs and symptoms of complications such
as cytokine storm/engraftment syndrome, serious infection,
and hyperacute graft versus host disease.
Methods: We retrospectively reviewed records of 244
patients who underwent hematopoietic SCT from January
2005 through May 2006. Electrolyte values were collected at
the time of admission for conditioning (time point A);
transplant day (+/- 1 day; time point B); and 2-4 days prior to
engraftment. Two-sided paired t-tests were conducted
comparing levels for each of the time points A and B
compared to pre-engraftment. For comparison between
groups, two-sided two-sample t-tests were conducted. No
adjustment was made for the multiplicity of testing. Patients
were grouped as follows: overall, by stem cell source
(apheresis, bone marrow, or cord), transplant type (alloge-
neic or autologous), and CD 34 cell dose (>5 or 5 x 106/kg,
for apheresis products only). Patients had their electrolyte
levels measured while in the hospital, and received stan-
dardized electrolyte replacements.
Results: Overall, the values for all the electrolytes two to four
days before engraftment were signiﬁcantly lower than at
time points A or B (P-value range <.001 to .01 e Table 1). We
concluded that drops in electrolyte levels precede neutrophil
engraftment after peripheral blood SCT. Being able to predict
neutrophil engraftment will help nurses be more aware of
possible SCT complications that may occur with
engraftment, and allow the nurses to work with the
medical team to intervene quickly.120
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Myeloablative chemotherapy/radiotherapy prior to
autologous hematopoietic stem cell transplant (AHSCT) is
a leading cause of mucositis associated with signiﬁcant
morbidity. Palifermin has been demonstrated to decrease the
incidence of severe mucositis in adults following total body
